Acrivon Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A proteomics-driven platform is advancing targeted cancer therapies, with lead asset ACR-368 showing high response rates and favorable safety in serous endometrial cancer. Rapid global trial expansion and a robust pipeline, including a dual WEE1/PKMYT1 inhibitor and a CDK11 inhibitor, support strong clinical and commercial potential.
-
ACR-368 showed a 52% response rate and favorable safety in serous endometrial cancer, addressing a major unmet need where current therapies are limited. Experts anticipate broad adoption in second- and third-line settings, with rapid global trial expansion and ongoing FDA engagement for potential accelerated approval.
-
The AP3 platform enables precision drug development, with ACR-368 showing high response rates in serous endometrial cancer and a favorable safety profile. ACR-2316 demonstrates activity in aggressive lung cancers, and preclinical ACR-6840 targets CDK11. IND for ACR-6840 is planned for Q4.
Fiscal Year 2025
-
The AP3 platform enables precision drug design, leading to strong clinical results for ACR-368 in heavily pretreated endometrial cancer patients, with a 35% response rate and favorable safety. Endometrial cancer is now the lead focus, with expanded financial runway and multiple pipeline updates expected this year.
Fiscal Year 2024
-
The AP3 platform enables precision drug matching in oncology, with ACR368 showing a 63% response rate in biomarker-positive endometrial cancer and a strong safety profile. Regulatory progress includes Fast Track and breakthrough designations, with plans for expansion into new indications and combination strategies.
-
Interim phase II data in endometrial cancer show a 63% confirmed response rate in biomarker-selected patients, with durable responses and a favorable safety profile. The AP3 platform enables precise patient selection and drug optimization, supporting ongoing expansion of the pipeline and regulatory engagement.